Showing 4181-4190 of 6036 results for "".
- Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy Clinical Trialhttps://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-geographic-atrophy-clinical-trial/2482248/Inflammasome Therapeutics announced the first patient has been dosed in a first-in-class clinical trial for a sustained release implant for geographic atrophy (GA) due to age-related macular degeneration (AMD). The phase 1 trial (ClinicalTrials.gov ID NCT06164587) is sponsored by the Univers
- Aldeyra Therapeutics Announces Planned Pivotal Clinical Trial for RP Drug Candidatehttps://modernod.com/news/aldeyra-therapeutics-announces-planned-pivotal-clinical-trial-for-retinitis-pigmentosa-drug-candidate/2482247/Aldeyra Therapeutics hosted the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City on April 25 where it presented recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
- RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Wet AMD Treatmenthttps://modernod.com/news/revopsis-secures-165-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-wet-amd-treatment/2482246/RevOpsis Therapeutics announced it has successfully closed its first seed funding round, raising $16.5 million to develop and commercialize treatments for chronic multifactorial diseases through the company's fully human multispecific proprietary Rev-Mod Platform. The 
- DigitalOptometrics Surpasses 2 Million Remote Eye Examshttps://modernod.com/news/digitaloptometrics-surpasses-2-million-remote-eye-exams/2482242/DigitalOptometrics announced it has surpassed 2 million remote comprehensive eye exams. DigitalOptometrics' remote eye exam platform is designed to allow optometrists to conduct comprehensive eye exams remotely, integrating video conferencing with remote operation of opht
- Ocugen Completes Dosing in Phase 1/2 Trial of OCU410 for Geographic Atrophyhttps://modernod.com/news/ocugen-advances-armada-trial-of-ocu410-to-treat-patients-with-geographic-atrophy/2482238/Ocugen announced dosing is complete in the second cohort of its phase 1/2 ArMaDa trial of OCU410, an adeno-associated viral vector 5 human RORA (AAV5-hRORA) gene therapy being developed for geographic atrophy (GA). Up to 13
- EyeSouth Partners Affiliates With Community Eye Care Specialists in New Yorkhttps://modernod.com/news/eyesouth-partners-affiliates-with-community-eye-care-specialists-in-new-york/2482233/EyeSouth Partners announced it has partnered with Community Eye Care Specialists, representing its first affiliation in New York, third affiliation in Pennsylvania. and 40th affiliation overall. Financial terms of the deal were not disclosed. EyeSouth is an eye care-focused ma
- In Japanese Study, Vabysmo Achieves Primary Endpoint in Phase 3 Study for Angioid Streakshttps://modernod.com/news/in-japanese-study-vabysmo-achieves-primary-endpoint-in-phase-3-study-for-angioid-streaks/2482231/Japan-based Chugai Pharmaceutical announced that the Japanese phase 3 study (NIHONBASHI study), evaluating Roche and Genentech's Vabysmo (faricimab) for angioid streaks associated with neovascularization, met its primary endpoint, demonstrating statistically signific
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- ViGeneron Announces First Patient Dosed in Phase 1b Trial of VG901 for the Intravitreal Treatment of RPhttps://modernod.com/news/vigeneron-announces-first-patient-dosed-in-phase-1b-trial-of-vg901-for-the-intravitreal-treatment-of-rp/2482224/ViGeneron announced that the first patient has been dosed in its phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage it
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als